CSF1R and giant cell tumor: Anti-CSF1R monoclonal antibodies have been proposed for cancer therapy for more than 10 years, and the only one in an active phase III clinical trial is RG7155 (emactuzumab), which has been tested for tenosynovial giant cell tumors (NCT05417789).